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Abstract
A reverse transcriptase (RT) cDNA, designated HERV-K-T47D-RT, was isolated from a hormonally treated human
breast cancer cell line. The protein product putative sequence is 97% identical to the human endogenous HERV-K
retroviral sequences. Recombinant T47D-RT protein was used to generate polyclonal antibodies. The expression of
HERV-K-T47D-RT protein increased in T47D cells after treatment with estrogen and progesterone. The RT-associated
DNA polymerase activity was substantially increased after over-expressing a chimeric YFP-HERV-K-T47D-RT pro-
tein in cells. This RT-associated polymerase activity was significantly reduced by mutating the active site sequence
YIDD to SIAA. Moreover, the endogenous RT activity observed in T47D cells was decreased by HERV-K-T47D-RT–
specific siRNA, confirming the dependence of the endogenous enzymatic activity. To assess HERV-K-T47D-RT
expression in human breast tumors, 110 paraffin sections of breast carcinoma biopsies were stained and sub-
jected to confocal analysis. Twenty-six percent (28/110) of the tumor tissues and 18% (15/85) of the adjacent nor-
mal tissue, from the same patients, expressed the RT. HERV-K-T47D-RT expression significantly correlates with
poor prognosis for disease-free patients and their overall survival. These results imply that HERV-K-T47D-RT might
be expressed in early malignancy and might serve as a novel prognostic marker for breast cancer. Furthermore,
these results provide evidence for the possible involvement of endogenous retrovirus in human breast carcinoma.
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Introduction
Breast cancer is the most common cancer among women in Western
society, and the second most deadly malignancy among women [1].
Approximately 10% of breast cancers are due to known genetic pre-
disposition [2,3], and approximately one third of the familial cases
are probably due to mutations in the BRCA1 or BRCA2 genes [4].
Since the discovery of the mouse mammary tumor virus (MMTV) as
an etiologic agent of murine mammary tumors [5], there has been an
interest in the possible existence of similar infectious agents in hu-
mans. The human genome contains a large variety of endogenous
retroviral sequences (HERVs; approximately 8% of the human ge-
nome) [6], of which the majority are highly defective [7,8]. In con-
trast to many defective HERV sequences, the HERV-K family shows
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a conservation of seeming intact retroviral genes [9]. These tran-
scripts possess open reading frames (ORFs) that can potentially en-
code for the complete Gag, Pol, and Env proteins. Therefore, out of
all known endogenous retrovirus families, the HERV-K is the most
likely to encode for complete and possibly infectious retroviruses
[10]. Retroviral-like particles were shown to be present in different
types of human tissues and cell lines. Human teratoma–derived parti-
cles (HTDV/HERV-K) were first observed in human teratocarcinoma
cell lines. These particles contain high–molecular weight RNA and a
reverse transcriptase (RT) [11]. It has been previously shown by others
and by us that the human breast carcinoma–derived cell line T47D
release retroviral-like particles that resemble type B virions [12,13].
These particles possess low RT activity and cross-react with antibodies
against the MMTV envelope protein, gp52 [14,15]. RT-encoding se-
quences with identity to MMTVand HERV-K10 were detected using
polymerase chain reaction (PCR) amplification of peripheral mononu-
clear cells cDNA (prepared from cellular mRNA) and genomic DNA,
with primers for conserved RT regions. These sequences were divided
into six groups, designated human endogenous MMTV-like (HML) 1
through 6 [16]. Three different retroviral sequences were isolated from
purified T47D particles [17]. One of the proviral pol sequences
showed an uninterrupted ORF that encodes for 241 amino acids with
65% identity to HERV-K10 [17]. Expression of an mRNA that en-
codes for a HERV-K RT ORF was shown in particles released from
hormonally treated T47D cells [18,19]. On the basis of the HERV-K
sequences, an RT with low activity was expressed from human bone
marrow cells [20]. HERV-K-env transcripts were detected in several
breast cancer cell lines and breast tumor tissues but not in nonmalignant
breast tissues [21]. The expression of HERV-K-env transcripts was 5- to
10-fold higher in breast cancer cell lines that were treated with estradiol
and progesterone, relative to untreated cells. HERV-K-env expression
was significantly higher in most breast cancer tissues than in normal
breast tissues [22]. Despite a lot of circumstantial evidence [17,18,
21,23], there is still no conclusive evidence for retroviral involvement
in human breast neoplasia. Because RT is a crucial enzyme in the retrovi-
ral reproductive cycle, there is high importance to isolate an RT-encoding
gene from human breast carcinoma cell lines and to confirm the exis-
tence of an active RTenzyme in these cells. In this work, an endogenous
RTenzyme was cloned from the breast carcinoma cell line T47D, and its
intracellular induction by steroid hormones and its activity were charac-
terized. We have also determined the level of HERV-K-T47D-RT pro-
tein expression in 110 breast cancer human tissue biopsies and showed a
significant positive correlation with the patient’s disease-free interval and
overall survival in breast cancer.
Materials and Methods
Cell Culture
The mammary carcinoma cell lines: T47D [24], MDA-MB-231,
BT549 (obtained from American Type Culture Collection, Manassas,
VA), the 293T cells (a human embryonic kidney cell line stably trans-
fected with SV40 large T-antigen), and the mouse mammary tumor cell
line (Mm5MT) [25] were all maintained in DMEM supplemented
with 10% heat-inactivated fetal calf serum (FCS; Invitrogen, Carlsbad,
CA), 1% sodium pyruvate, and 1% penicillin–streptomycin. The
human mammary epithelial cell line (HB2), which is a clonal deriv-
ative of a nontumorigenic mammary epithelial cells line, MTSV1-7
[26], was maintained in DMEM supplemented with heat-inactivated
10% FCS, 10 μg/ml insulin, and 0.5 μg/ml hydrocortisone. For hor-
mone stimulation studies, cells were grown in phenol red–free
DMEM (Invitrogen) and were treated with 10−8 M β-estradiol (Sigma-
Aldrich, St. Louis, MO) supplemented with 1% dialyzed FCS for
48 hours followed by treatment with 10−8 M progesterone (Sigma-
Aldrich) for 48 hours. Mm5MT cells were treated with 10−6 M dexa-
methasone (Difco, Detroit, MI).
Cloning and Purification of Recombinant RT
Two primer sets were used to amplify HERV-K-RT genes by reverse
transcription–polymerase chain reaction (RT-PCR). The short (1.4 kb)
RT segment was amplified by primer set based on the HERV-K-pol
published sequence [18] HERV-K-short-sense 5′-GGGAATTCCA-
TATGCCACTAACTTGGAAAACAGAAAAAC-3′ and HERV-K-
short-antisense 5′-GGCGCAAGCTTGTTCTCTCGGCCCTGTG-
TAA-3′. The sense and antisense primers contain either an NdeI or
Hind III restriction enzyme site, respectively (underlined in the se-
quences). The full-length RT (1.8 kb) was amplified with a primer
set based on the HERV-K (clone 10.1) published sequence [20].
The sense HERV-K-RT primer was 5′-GGAATTCGCATGCAA-
TAAATCAAGA AAGAGAAGGAATAG-3′ and the antisense one
was 5′-CCGTCGAAGCTTTA AGCATGAAGTTCTTGTGC-3′.
These primers contain either an SphI or an Hind III restriction enzyme
site, respectively (underlined in the sequences). The antisense primer
provides a UAA stop codon (marked in bold in the sequence). This
primer set was also used to amplify HERV-K-RT/HTDV from the
pcGPK31ΔLTR vector containing the HERV-K pol, gag, and env
genes [27], generously given by Dr. Ralf Tonjes (Paul-Ehrlich-Institut,
Langen, Germany). The PCR products were digested with the proper
restriction enzymes (NdeI or SphI and Hind III) to allow the in-frame
fusion of the RT ORFs into a pT5M-based plasmid, which was engi-
neered to express a six-His tag fused to the amino-terminus of the re-
combinant protein. All PCR products were sequenced.
The two versions of the recombinant His-tagged proteins were ex-
pressed in BL21(DE3) pLysS strain of Escherichia coli (Stratagene, La
Jolla, CA) by induction with 1 mM isopropyl-β-d-thiogalactopyranoside
(IPTG). The His-Tag HERV-K-T47D-RT-short recombinant pro-
tein (42 kDa) was purified under denaturing conditions. The bacte-
ria pellet was lysed with 100 mM sodium phosphate, 10 mM Tris,
8 M urea, pH 8.0, and was purified with Ni-NTA superflow (Qiagen,
Valencia, CA) following the manufacturer’s instructions (the equilibra-
tion and washing steps were performed with the same buffer). The
protein was eluted with stepwise decreasing pH solutions of pH 6.3,
5.9, and 4.5 containing 100 mM sodium phosphate, 10 mM Tris, and
8 M urea. The denatured protein was refolded by a gradual removal of
urea employing a stepwise dialysis from 8 M urea to no urea in PBS.
The full-length HERV-K/HTDV recombinant protein (66 kDa)
and a recombinant MMTV-RT protein were expressed in bacteria
and purified in native conditions as described in detail previously [28].
Generation of Polyclonal Antibodies
To generate HERV-K-T47D-RT antiserum, the purified His-
tagged short HERV-K-T47D-RTwas injected into two rabbits, using
standard immunization procedures [29]. For purification, the sera were
absorbed with an acetone powder of BL21(DE3) pLysS bacteria pre-
pared as described in detail [30].
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from 1 × 107 hormonally treated T47D
cells, using TRI Reagent (Sigma-Aldrich). The first-strand cDNA
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was synthesized by incubating 5 μg of total RNA with the random
primers (GTGAGCTCC, CCAGTACAG) and RT (Superscript II,
Invitrogen) according to the manufacturer’s instructions (in a volume
of 20 μl). All PCR reactions were performed using 5 μl of the RT
products with DynaZyme DNA polymerase (Finnzymes, Helsinki,
Finland) with the appropriate primers according to the manufac-
turer’s instructions. All PCR reactions were conducted for 35 cycles,
each of 1 minute at 94°C, 1 minute at the primer-adjusted melting
temperature (Tm), and 2 minutes at 72°C. Negative controls were
performed with identical aliquots of cDNA synthesis reaction that
was performed with no RT present. The PCR products were ana-
lyzed by electrophoresis on Tris–acetate–EDTA 1% agarose gels for
fragments with the appropriate lengths.
Plasmid Construction and Sequencing
To generate the yellow fluorescence protein (YFP) tag T47D-
HERV-K-RT, the full-length RT-encoding gene was amplified by
RT-PCR (as described previously) with the following set of primers:
5′-CCGCGCCCCTCGAGCT AATAAATCAAGAAAGAGAAG-
GAATAG-3 ′ and 5 ′ -CCGTCGAAGCTTTA AGCAT-
GAAGTTCTTGTGC-3′. The sense and antisense primers contain
a XhoI and Hind III restriction enzyme sites, respectively (underlined
in the sequences). The antisense primers provide a UAA stop codon
(marked in bold in the antisense sequences). The PCR product, pre-
digested with XhoI and Hind III, was ligated in-frame into the XhoI and
Hind III-cleaved pYFP-C1 expression vector (Clontech Laboratories
Inc., Palo Alto, CA). The complete sequence of the HERV-K-T47D-
RT gene and the short HERV-K-T47D-RT gene were confirmed
by DNA sequencing of the pYFP-HERV-K-T47D-RT plasmid and
the pT5-HERV-K-T47D-RT-short plasmid, respectively. For full-
length sequencing, we used several internal sequencing primers.
New primers include the sense DNA oligonucleotides pEYFP5′-F
(5′-CATGGTCCTGCTGGAGTTCGTG-3′), T47D-RT-642-F (5′-
GACTGGC AATAGCATCTGATAAG-3′), T47D-RT-1521-F
(5′-GTACAGGCTACAAGGGA TGTTG-3′) and the antisense
primer T47D-RT-1350-R (5′-GTAGTCAATTTTAAGAACTG
GAAGATC-3′). The nucleotide sequence of the full-length HERV-K-
T47D-RT gene in this study has been deposited in the GenBank data-
base under accession number DQ821442.
The mutated YFP-HERV-K-T47D-RTwas produced by site-directed
mutagenesis using the Stratagene QuickChange kit (Stratagene), follow-
ing the manufacturer’s protocol. Using the pYFP-HERV-K-T47D-RT
plasmid as a template, three point mutations were introduced with
the following oligos: sense – 5′-GAGAGAAAAGTTTTCAGACTGT-
TATATTATTC ATTCTATTGCTGCTATTTTATGTGCTGCA-
GAAACGAAAG-3′; and antisense – 5′-CTTTCGTTTCTGCAGC-
ACATAAAATAGCAGCAATAGAATGAATAATA TAACAGTCTGA-
AAACTTTTCTCTC-3′ (all mutated nucleotides were A to C transi-
tions, marked in bold and underlined). The mutations were verified
by sequencing.
Construction of siRNA Expression Vectors
The mammalian expression vector pSUPER.retro (pSR) (Oligoen-
gine, Seattle, WA) was used for the expression of siRNA [31]. To
produce an intact target recognition sequence to suppress HERV-
K-T47D-RT expression by pSUPER− HERV-K-T47D-RT vector,
the siRNA sequences were designed to correspond to nucleotide po-
sitions 202–223 of the HERV-K-T47D-RT–short gene (marked in
bold in the following sequences): sense strand – 5′-GATCCCC-
ATCAGTGGCCGCTACCAAATTCAAGAGATTTGGTAGC-
GGCCACTGATTTTTTGGAAA-3′ and antisense strand – 5′-
TCGATTTCCAAAAAATCAG TGGCCGCTACCAAATCT-
CTTGAATTTGGTAGCGGCCACTGATGGG-3′. Selection of
the 202–223 nucleotide region was based on its location within
the HERV-K-T47D-RT–encoding gene and its conservation in the
HERV-K/HTDV gene sequence. siRNA was annealed as previously
described [32]. The oligo-annealing buffer was made with 100 mM
potassium acetate, 30 mM HEPES–KOH (pH 7.4), and 2 mM Mg-
acetate. pSUPER vector was digested with XhoI and BglII restriction
endonucleases. Subsequently, the oligos of HERV-K-T47D-RT siRNA
were inserted. The sequence of the plasmids of the pSUPER− HERV-
K-RTsiRNAwas confirmed by sequencing. The control pSUPER.retro-
GFP vector was kindly given by Dr. Shilo’s laboratory (Tel Aviv University,
Tel-Aviv, Israel). All transient transfections were performed using
293T cells. Cells were cotransfected with 4 μg of the pYFP-HERV-K-
T47D-RT plasmid and with 15 μg of the pSUPER-siRNA or pSUPER
empty vector as negative control.
Cell Transfection
293T cells were transiently transfected at 60% to 70% confluence
by calcium phosphate precipitation transfection [33]. T47D cells
(8 × 106) were transfected with 20 μg of DNA (recombinant or empty
vector) by electroporation (0.25 V, 960 μF) and immediately plated
in tissue culture dishes containing growth medium (supplemented
DMEM). G418 (2 mg/ml) was added 24 hours after transfection,
and stable transfectants were selected within 14 days or after. The same
procedure was used to generate all stable transfectants.
Northern Blot Analysis
The DNA probes for hybridization were prepared as follows:
HERV-K-RT probe was generated by digestion of the pT5-HERV-
K-T47D-RT-short vector with NdeI and Hind III. MMTV-RT probe
was generated by digestion of the pUC112N-MMTV-RT-(3A) vec-
tor [28] with NotI and Hind III. HERV-K− gag and HERV-K− env
probes were generated by PCR with the pcGPK31ΔLTR vector [27],
using the following primers, respectively:
gag:
sense – 5′-GGGAATTCCATATGGAAGCTAGGGT GA-
TAATGGGGC-3′;





antisense – 5′-CCGTCGAAGCTTAGAGCTG TTGGGTA-
CACCTG-3′.
18S cDNA was purchased from Clontech Laboratories Inc.
Total RNA was prepared from cultured cells using TRI Reagent
(Sigma-Aldrich). Samples containing 20 μg of RNA were separated
on 1.2% agarose/2% formaldehyde gels and were blotted to nylon
membrane Hybond-N (Amersham Pharmacia, Buckinghamshire,
England). The membrane was prehybridized for 4 hours in 5 ×
SSC, 5 × Denhardt’s solution, 50% formamide, 0.1% SDS, and
200 μg/ml denatured salmon sperm DNA at 42°C. The DNA
probes were labeled with [α-32P]dCTP using NEBlot Kit and were
added to the hybridization buffer for overnight incubation at 42°C.
Then, the membrane was washed three times at 42°C in 2 × SSC,
Neoplasia Vol. 10, No. 6, 2008 Reverse Transcriptase Encoded by the Human HERV-K Golan et al. 523
0.1% SDS for 20 minutes, followed by 1 to 0.1 × SSC, 0.1% SDS at
42°C (salt concentration and number of washing were adjusted for
each probe). For reprobing, the membrane was stripped in 0.1% SDS
at 100°C for 30 minutes.
Preparation of Cell Lysates
Confluent cells (5 × 106) were washed in PBS and resuspended
in 150 μl of lysis buffer [20 mM Tris–HCl, pH 7.8, 100 mM NaCl,
50 mM NaF, 1% NP40, 0.1% SDS, 2 mM EDTA, 10% glycerol
and protease inhibitors cocktail EDTA-free (Boehringer, Mannheim,
Germany)]. Cell lysates were left on ice for 10 minutes and then cen-
trifuged at 14,000g for 5 minutes at 4°C, and protein concentration
was quantified by BCA kit (Pierce, Rockford, IL).
Western Blot Analysis
SDS-PAGE was performed in reducing conditions in 8% or 9%
acrylamide gels (acrylamide/bisacrylamide ratio, 40:1 w/w). Approxi-
mately 100 to 200 μg of whole-cell protein extract were applied to
each lane. For Western blot analysis, proteins were electrophoretically
transferred to 0.2-μm-thick nitrocellulose membranes. Then, the
membranes were blocked for 1 hour at room temperature in 5%
milk/PBS. Primary antibodies were used as follows: anti–T47D-RT
at a 1:250 dilution, anti-GFP (Santa Cruz Biotechnology, Santa
Cruz, CA) 1:200, and anti–β-actin 1:1500 (Chemicon, Temecula,
CA), all diluted in milk/PBS for 16 hours at 4°C. The membranes
were washed in 0.2% Tween–PBS (PBST) and incubated with HRP-
conjugated antirabbit IgG diluted 1:40,000 or antimouse IgG di-
luted 1:20,000 (Jackson ImmunoResearch Laboratories, West Grove,
PA). Membranes were washed in 0.2% PBST, and enhanced chemi-
luminescence (Pierce) was performed. For reincubation, the mem-
brane was subjected to stripping with a fresh solution of Ponceau
S stain (0.2% Ponceau in a solution of 3% trichloroacetic acid in H2O).
Immunofluorescence Staining and Confocal Analysis
Cells. Hormonally treated or untreated T47D cells (1 × 104) were
grown in Lab-Tek chamber slides (Nalgene Nunc International, Na-
perville, IL). After 2 days, the cells were washed twice with PBS and
fixed for 10 minutes at room temperature in 4% paraformaldehyde/
PBS, washed three times with PBS, and permeabilized for 10 min-
utes in 0.5% Triton X-100 in PBS. Then, blocking was done in 1%
BSA/10% normal donkey serum/PBS for 30 minutes at room tem-
perature. The cells were subsequently incubated with the primary
antibodies. The antibodies anti–T47D-RT or preimmune rabbit se-
rum [normal rabbit serum (NRS)] were diluted 1:10 in primary an-
tibody dilution buffer (green buffer; purchased from Biomeda
Corporation, Foster City, CA) and incubated for 16 hours at 4°C.
The cells were then washed three times in PBS and incubated for
1 hour in the dark with the secondary antibody (rhodamine- or
FITC-conjugated donkey antirabbit IgG diluted 1:200 in PBS).
Slides were then washed in PBS and mounted with coverslips using
Gel-Mount (Biomeda).
Tissues. Tissues from malignant breast lesions were formalin-fixed
and embedded in paraffin. All the tissues were obtained from the
Oncology Department, Tel Aviv Sourasky Medical Center (Tel Aviv,
Israel) with the approval of the institutional Helsinki Committee. Se-
rial sections (5-μm thick) were prepared from the blocks and pro-
cessed as described. The slides were deparaffinized, washed in PBS,
and incubated with AutoZyme (Biomeda) for 10 minutes at 37°C.
The tissue sections were then blocked and stained as described pre-
viously for cells. For live cells YFP visualization, cells were grown on
12-mm round glass coverslips, compatible for confocal microscopy.
Samples were analyzed using a 410 Zeiss (Obercocen, Germany)
confocal laser scan microscope (CLSM) with the following configu-
ration: 25 mW krypton/argon (488 and 568 nm) and HeNe (633 nm)
laser lines. When comparing fluorescence intensities, identical CLSM
parameters (e.g., scanning line, laser light, contrast, and brightness)
were used nearly identical to methods used previously for breast cancer
analysis [34,35]. To compare the relative levels of protein expression,
we have used the average area intensity (AAI) image analysis procedure
for cell immunostains, and we also used mean square deviation of the
intensity value, entropy, and log2 entropy calculations for the tissue
stains. The image analysis calculations were done on several micro-
scopic fields (3–10), using the MICA software (Cytoview, Petach
Tikva, Israel). Variance was analyzed by 2-tailed analysis of variance.
RT Assay
Colorimetric reverse transcriptase activity was assayed by using the
colorimetric HS sensitivity RT kit (Cavidi, Upsalla, Sweden) in accor-
dance with the manufacturer’s directions. Radioactive RNA-dependent
DNA polymerase (RDDP) activity was assayed by measuring the in-
corporation of [3H]dTTP to the poly(rA)·oligo(dT)12–18 template
primer as in the study of Shaharabany et al. [36].
Statistics
The results are expressed as the mean ± SEM. Student’s t test was
used to analyze statistical differences between the control and exper-
imental groups. Differences were considered statistically significant at
P < .05. Analyses of overall survival were performed with Kaplan–
Meier analysis [37]. Computations were performed using SAS (SAS
Institute, Cary, NC). Cutoff point was selected as was previously de-
scribed in Altstock et al. [38].
Results
Isolation of the Coding Sequence for the HERV-K-T47D-RT—
Its Cloning, Expression, Purification, and Generation of
Polyclonal Antibodies
To clone the specific mRNA and express its cognate active RT,
total RNA was isolated from T47D cells that were treated with the
steroid hormones estrogen and progesterone. The transcripts were
amplified by RT-PCR, using two primers sets: primers for shorter ORF
transcript [18], and primers for full-length transcript [20]. The PCR
products were cloned and sequenced.
The putative amino acid sequence of HERV-K-T47D-RT–encoding
gene shows a 97% identity with the published sequence encoded by
the HERV-K-pol gene from T47D particles [18] and by the human
HERV-K endogenous retroviral sequence from teratocarcinoma GH
cell line (HTDV-human teratocarcinoma–derived virus) [39]. HERV-
K-T47D-RT possesses low identity with MMTV-RT (41%). HERV-
K− Phylogenetic comparison shows that the HERV-K-T47D-RT
sequence belongs to an HERV-K subgroup called HML-2 (human
MMTV like-2; Figure W1). Bioinformatic analysis demonstrated
that HERV-K-RT sequence is present in many chromosomes in
the human genome. The HERV-K-RT sequence has more than 98%
similarity to chromosomes: 1, 3, 5, 6, 7, 8, 10, 11, 19, 21, and 22.
The HERV-K-T47D-RT amino acid sequence is almost identical to
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the HERV-K-pol gene that was isolated from particles released by
T47D cells [18]. However, our newly cloned sequence is much differ-
ent (59%) from the HERV-K-T47D-1 that was also isolated from
T47D particles by Seifarth et al. [17]. T47D-RT exhibits the catalyt-
ically central DNA polymerase YIDD motif, a derivate of the YXDD
motif, which is conserved in all HERV-K RT sequences [40]. The
short transcript of HERV-K-T47D-RT was cloned into the same
E. coli expression vector pT5, for producing 6His-RT fusion protein.
The 6His-HERV-K-T47D-RT fragment was used to generate specific
rabbit antibodies (designated anti–T47D-RT). The recombinant full-
length HERV-K-RT protein (66 kDa) cross-reacted with the anti-
T47D antibody (Figure W2). However, the anti–T47D-RT antibody
was shown to be specific to HERV-K-RT and did not cross-react with
the recombinant MMTV-RT (Figure W2).
Hormonally Induced Expression of the HERV-K-T47D-RT
The HERV-K viral expression is increased when T47D cells are
treated with the steroid hormones estrogen and progesterone, as de-
scribed by our group and others [12,13,18]. Therefore, the effect of
steroid hormones treatment on RT protein expression was assessed.
The HERV-K-T47D-RT protein expression level in response to hor-
monal treatment was examined in several breast carcinoma cell lines
(T47D, MCF7, MDA-MB-231, and BT549) and in the normal human
breast cell line HB2 (Figure 1A). The cells were treated with β-estradiol
for 48 hours, followed by progesterone treatment for an additional
48 hours. A twofold increase in the level of the HERV-K-T47D-RT
protein was observed in T47D cells after hormonal treatment (as was
measured by densitometry; data not shown). The normal human
breast cell line HB2 did not express any detectable levels of the
HERV-K-T47D-RTwith or without hormone treatment. The high-
est basal level of HERV-K-T47D-RT protein expression was ob-
served in the metastatic breast cancer cell lines MDA-MB-231 and
BT549. The level of protein did not increase significantly after hor-
monal treatment in these cell lines (Figure 1A). Because a significant
hormonal induction was seen only in T47D cells, we have further
characterized this induction by a single-cell resolution, using anti–
T47D-RT antibodies by immunofluorescence technique. Ten differ-
ent fields were taken from each staining, and the average fluorescent
area intensity was calculated. HERV-K-T47D-RTexpression increased
by 30% in response to hormone treatment (P = .006; Figure 1, B and
C ). To our knowledge, this is the first time that a hormonal induction
of a viral-related RT protein is observed in human breast carcinoma
cells. We have also tested the hormone-induced expression of the
HERV-K viral gag, pol (RT), and env mRNA in T47D cells. T47D
cells were hormonally treated as described previously. Mm5MT cells
(mouse mammary carcinoma cell line expressing MMTV), treated
with dexamethasone, served as a positive control for the MMTV RT
probe and a negative one for the HERV-K-T47D-RT. Northern blot
analyses demonstrated that, in response to hormonal treatment, expres-
sion levels of HERV-K-T47D pol (RT), HERV-K-gag and -env tran-
scripts increased significantly, albeit to different levels indicating
different mRNA stabilities (Figure 1,D and E ). The MMTV-RT probe
served as a negative control, and 18S rRNA probe served as a loading
control. As could be expected from other retroviruses, the HERV-K-
env probe reacted with the full mRNA (8.8 kb) and with spliced
mRNA of approximately 1.6 kb. The spliced env mRNA was ex-
pressed 20-fold lower relative to the unspliced mRNA. As expected,
no cross-hybridization was detected between the HERV-K-T47D-RT
and the MMTV-RT transcripts (Figure 1D).
Over-Expression of HERV-K-T47D-RT Shows an Induction of
the RT-Associated RNA-Dependent DNA Polymerase Activity
That Is Abolished By Active Site Mutations
Because of the high sequence identity, a full HERV-K-RT/HTDV
sequence [27,39] that was isolated from teratocarcinoma cells was re-
combinantly expressed. The purified HERV-K-RTenzyme was tested
by in vitro assay system. It possesses an RNA-dependent DNA poly-
merase (RDDP) activity that is the hallmark activity of all known
RTs [20,28]. Similar to the data available to all the recombinant
HERV-RTs examined so far that were shown to have low catalytic
activities [20,41], this level of the HERV-K-RT activity is significant,
albeit low, in comparison to MMTV-RT (data not shown).
To further demonstrate that the HERV-K-T47D-RT exhibits also
an in vivo enzymatic activity in mammalian cells, we constructed a
plasmid encoding for the chimeric protein YFP-HERV-K-T47D-RT.
Because the N-terminal extension is not expected to change the ac-
tivity level of the RT [20] and may even stabilize it [28], we have
chosen to use a YFP chimeric protein for easier identification of the
positive clones. The YFP-HERV-K-T47D-RT plasmid was used to
transiently transfect 293T cells and stably transfect T47D cells. An
empty pYFP-C1 plasmid served as control. The chimeric protein ex-
pressing the wild type (WT) YFP-HERV-K-T47D-RT was expressed
in both cells, as seen by CLSM analysis (Figure 2A). The chimeric
YFP-HERV-K-T47D-RT protein was localized to the cytoplasm and
showed lower intensity compared with cells transfected with the YFP-
expressing vector alone (as expected for a chimeric protein). The
YXDD motif, where X is an isoleucine in the specific case of HERV-K,
is highly conserved among various retroviral RTs [40,42]. Several
studies have shown that Y→ S substitutions in the YXDD motif can
abolish the polymerase activity of HIV-RT [43] and MuLV-RT [44].
To prove the HERV-K-T47D-RT–specific activity, we have mutated
the YIDD motif, starting at position 184 of the chimeric YFP-HERV-
K-T47D-RT, to SIAA using the direct point mutagenesis methodology.
The mutated YFP-HERV-K-T47D-RT–expressing plasmid was also
used to transiently transfect 293T cells and stably transfect T47D
cells. Protein extracts were purified from all transfected cells and were
subjected to Western blot analysis using anti–GFP-Ab (which cross-
reacts with YFP; Figure 2B). In the cells transfected with the control
plasmid, a lower band of 27-kDa YFP was observed (not shown).
The amounts of total protein subjected to the Western blot analysis
were normalized to achieve equal expression levels of the different
RTs. The same extracts were also subjected to highly sensitive RT
RNA-dependent DNA polymerase (RDDP) colorimetric activity assay
(Figure 2C ). The results represent a typical experiment that was re-
peated three times, with triplicates or duplicates each time. A signifi-
cant polymerase activity was observed in both extracts of 293T cells
and T47D cells transfected with the WT YFP-HERV-K-T47D-RT
protein. Extracts of cells, transfected with the mutated YFP-HERV-
K-T47D-RT, exhibited very low activity levels similar to the control.
The basal activity in T47D cells (Figure 2C ) is most probably due to
the activity of the endogenous RT. These results indicate that the
HERV-K-T47D-RT is enzymatically active in mammalian cells and
that the observed activity is specific to this RT enzyme.
HERV-K-T47D-RT Expression Knockdown Suppresses the
Cellular RT Expression Levels and Its Enzymatic Activity
To prove that the endogenous RT-associated activity, seen in the
transfected T47D cells, is derived specifically from the HERV-K-
T47D-RT activity, we have used RNA interference to knockdown
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Figure 1. Hormonal-induced expression of the HERV-K-T47D-RT protein. (A) Western blot analysis of a blot containing purified HERV-K-RT and
extracts from different human breast cell lines: T47D, MCF7, MDA-MB-231, BT549, and HB2. The cells were either untreated (−) or treated
(+) with steroid hormones, as described in the Materials and Methods section. The blot was incubated with the anti–T47D-RT antibody.
Afterwards, the blot was striped and incubated with anti–β-actin antibodies (serving as a loading control). (B) Immunofluorescence staining:
T47D were untreated (−) or treated (+) with β-estradiol and progesterone as described in the Materials and Methods section. The cells were
fixed and stained with anti-T47D or with preimmune serum (NRS) as control. The stained cells were analyzed using CLSM. Scale bars, 50 μm.
(C) Comparison between anti–HERV-K-T47D-RT and NRS staining (*P = .00001, Student’s t test) and untreated versus treated cells’ HERV-K-
T47D-RT staining levels (P = .0008, Student’s t test) using average fluorescence intensity per area by MICA software on 10 fields of each
staining. (D) The level of HERV-K-T47D, HERV-K-T47D-gag, and HERV-K-T47D-envmRNA expression was examined by Northern blot analysis
of total cellular RNA isolated from either Mm5MT cells untreated (−) or hormonally treated (+) with dexamethasone, or from T47D cells
untreated or treated with β-estradiol and progesterone as described in the Materials and Methods section. The same blot was separately
probed with randomly primed 32P-labeled HERV-K-T47D-pol(RT), HERV-K-T47D-gag, HERV-K-T47D-env, MMTV-pol DNA, or with 18S rRNA as
control. To avoid remnant signal, the blot was stripped between each probe and exposed overnight to a film to confirm that there is no
remnant signal from the other probes. The RT, gag, and env were hybridized to the same-sized 8.8-kb band, representing the full transcript.
The env probe was hybridized with an additional 1.6-kb transcript representing the alternative splice variant, demonstrating a 20-fold less-
intensified signal. To better demonstrate the 1.6-kb faint band, the image was intensified. (E) The mRNA expression was quantified by den-
sitometric scanning. The signals were normalized to the intensity of signal obtained with the 18S rRNA probe.
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its expression. The efficiency of the siRNA was confirmed by tran-
sient cotransfection of 293T cells with the pYFP-HERV-K-T47D-
RT plasmid and either the pSUPER-siRNA plasmid or an empty
pSUPER plasmid as control. The data show that the exogenous
YFP-HERV-K-T47D-RT expression levels and the RT-associated po-
lymerase activity were significantly reduced by 70% to 75% with
DNA of the pSUPER-siRNA compared to the pSUPER empty vec-
tor (Figure 3, A–D). Because the siRNA was efficient in reducing the
exogenous YFP-HERV-K-T47D-RT levels, the hairpin siRNA was
recloned to pRetro.super expression system to reduce the endogenous
HERV-K-T47D-RT levels. T47D cells were stably transfected with the
specific pRetro-siRNA-RT or with irrelevant pRetro-siRNA-GFP. The
T47D pRetro-siRNA-RT stable clones, which showed a significant re-
duction in HERV-K-T47D-RT protein expression levels (compared
with the control siRNA-GFP; Figure 4A), were also subjected to the
RT-associated polymerase activity assay (Figure 4B). The results dem-
onstrate that the RT polymerase activity decreased significantly by 60%
to 80% compared with the control siRNA, with a high correlation to
the protein expression levels (Figure 4B). This suggests that most of the
endogenous enzymatic activity obtained in T47D cells is specific to the
HERV-K-T47D-RT protein. To further examine the endogenous en-
zymatic activity, retroviral-like particles were purified from high-spin
pellet of hormonally treated T47D cells supernatant. Representative re-
sults of three separate experiments showed a 20-fold induction in the
specific RT polymerase activity in the pellet of hormonally treated
T47D cells compared with the pellet of untreated T47D cells (Fig-
ure 4C ). These results indicate that the endogenous HERV-K-RT is
also active in particles released from hormonally treated T47D cells.
Figure 2. Over-expression of the chimeric YFP-HERV-K-T47D-RT enzyme. (A) CLSM analysis of 293T cells (left panel) and T47D cells
(right panel) transiently or stably transfected, respectively, either with pYFP-C1 (row 1) or with pYFP-HERV-K-T47D-RT (row 2). Scale bars,
50 μm. (B) Western blot analysis of protein extracts obtained from 293T (left panel) and T47D cells (right panel) transfected with pYFP-
C1, with wild type (WT) pYFP-HERV-K-T47D-RT, or with the mutated pYFP-HERV-K-T47D-RT. The blots were incubated with anti-GFP
antibody. As a loading control, the same blots were incubated with anti–β-actin antibody. (C) RT-associated DNA polymerase colorimet-
ric activity assay was performed on the same protein extracts as in panel (B), from either the 293T cells (left) or the T47D cells (right). The
activity was normalized to the HERV-KT47D-RT–transfected cells’ activity that was set to 100%. The RT assay was repeated three times,
and this is a representative experiment.
Neoplasia Vol. 10, No. 6, 2008 Reverse Transcriptase Encoded by the Human HERV-K Golan et al. 527
Detection of the HERV-K-T47D-RT Protein in Breast Cancer
Tissues and Its Implications as a Prognostic Marker
To investigate the expression of the HERV-K-T47D-RT in human
breast carcinoma, 110 breast cancer biopsies from patients with 5 to
10 years of follow-up were immunostained. Serial sections of breast
carcinoma were immunostained with anti–T47D-RT antibody or
with NRS as a control. Subsequently, Nomarski and fluorescence
CLSM images of both staining were acquired (three to five microscopic
fields for each case). Representative image pairs, showing the varying
levels of the HERV-K-T47D-RT protein expression versus the NRS
control staining, are shown in Figure 5A. HERV-K-T47D-RT staining
in the tumor tissue is shown in Figure 5A (a–d). The first two pairs of
images demonstrate positive HERV-K-T47D-RT expression, where
the RT staining is higher than the NRS control (Figure 5A, a vs c
and b vs d, respectively). HERV-K-T47D-RTstaining in normal tissues
adjacent to the tumor tissue is shown Figure 5A (e–h). The fourth pair
of images demonstrates a typical section with no detectable HERV-K-
T47D-RT expression (Figure 5A, f and h). We initially used an image
analysis program (MICA) to calculate the simplest pixel-based image
numerical descriptors, such as the AAI value, mean square deviation
of the intensity value, entropy, and log2 entropy. A histogram of the
AAI ratio (anti–T47D-RT/NRS) demonstrates the distribution of
staining levels in the tumor tissue (Figure 5B). The cutoff level between
positive and negative HERV-K-T47D-RT stainings (>1.2) was deter-
mined based on the 25% of the patients with the highest expression
level, as we have previously done for another marker [38]. Of 110 tu-
mors, 28 (26%) express the HERV-K-T47D-RT. In the adjacent nor-
mal tissue of the same sections, 15 (18%) of 85 tissues express the RT
protein. Interestingly, there was a high correlation between the positive
staining for the HERV-K-RT in the adjacent normal tissue and the
positive staining in the tumor tissue.
A Kaplan–Meier analysis showed that patients, whose tumors over-
expressed HERV-K-T47D-RT, had a significantly shorter metastasis-
free survival (P = .004; Figure 5C ) and shorter overall survival (P =
.0034; Figure 5D) in comparison with other patients whose tumors
did not over-express HERV-K-T47D-RT. The cutoff values of AAI
ratios = 1.2 (see Materials and Methods section) produced statisti-
cally significant results (Figure 5, C and D). The other image analysis
Figure 3. Knockdown of the chimeric YFP-HERV-K-T47D-RT enzyme. (A) Confocal analysis of the 293T cells cotransfected with: 1) ex-
ogenous RT-expressing gene and pSUPER empty vector (EV) or 2) exogenous RT-expressing gene and pSUPER-siRNA. Two represen-
tative fields are shown. Scale bars, 50 μm. (B) Comparison of the average fluorescence intensity per area, of 10 different fields (MICA
software), between the two transfections shown previously (A). *P = .0001 (analysis of variance). (C) Western blot analysis of an extract
of 293T cells transfected with: 1) pYFP-C1, 2) cotransfected with YFP-HERV-K-T47D-RT and with pSUPER-EV, and 3) cotransfected with
YFP-HERV-K-T47D-RT and pSUPER-siRNA. The blots were incubated with anti–T47D-RT antiserum (upper panel) and anti–β-actin (lower
panel). (D, left panel) The protein expression levels were quantified by densitometric scanning. The signals were normalized to the
intensity of signal obtained with the anti–β-actin. Gray bars represent percentage protein levels in cells transfected with pSUPER-EV
(100%), and the white bars represent percentage protein levels in cells transfected with pSUPER-siRNA. (D, right panel) Colorimetric RT
activity assay was performed with protein extracts form the same transfected cells as in panel (C) (a representative experiment out of
three). The activity of the control cells (pSUPER-EV transfectant) were set to 100% (gray bars).
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calculations produced very similar results (data not shown). These re-
sults clearly indicate that HERV-K-T47D-RT expression correlates
with breast cancer patients’ poor prognosis. Furthermore, we have also
analyzed the potential correlations between HERV-K-T47D-RT over-
expression and other clinical parameters, including age, clinical stage,
menopausal, estrogen receptor status, and progesterone receptor status
(patients with incomplete clinical parameters were included in the
unknown group). HERV-K-T47D-RT over-expression correlates with
age (P = .04) and distant metastasis (P = .05; Table 1). These results
suggest that the HERV-K-T47D-RT can be reliably used as a novel
independent prognostic marker for both metastasis and death risk in
human breast carcinoma.
Discussion
After years of intensive search for retroviral-related factor(s) in-
volved in human breast cancer, different clues were found to show
retroviral involvements in the disease. However, viral etiology was
not convincingly proven. Most of the studies prove the existence of
DNA that encodes for ORFs of retroviral genes in human breast can-
cer cell lines [13,17,18]. Few studies have shown the over-expression
of mRNA species encoding for the retroviral Env protein in human
breast cancer cell lines and biopsies [21,23]. However, as far as we
know, there are no reports showing the selective expression of the
Pol and Gag viral proteins in human breast cancer.
In this work, we have isolated a gene that encodes the HERV-
K-RT from the human breast carcinoma cell line T47D. The puta-
tive sequence of the RT encoded by this new gene possesses high
identity (96%) with a sequence of the pol gene product of HERV-
K10, the first full-length provirus also isolated from T47D cells [13].
The sequence of the HERV-K-T47D-RT protein possesses high
identity (97%) with the sequence of the product of pol isolated from
particles released from T47D cells [18] and only 71% identity with
the sequence encoded by the comparable gene isolated from similar
particles that belongs to other HERV-K subfamily [17]. Phylogenetic
analysis showed that the HERV-K-T47D-RT, isolated by us in the
present study, belongs to the HML-2 subfamily as the HERV-K10
(also expressed in T47D cells) and is closely related to HERV-K se-
quences. It seems that, in T47D cells, there are several HERV-K
(HML-2) sequences distinctive from each other by only a few nu-
cleotides. It is estimated that the HERV-K (HML-2) integration
event occurred approximately 1.2 Ma (based on minimal difference
between the LTRs) and thus is considered an evolutionary young
HERV-K family [9]. This may be the cause for the conserved active
genes in this family compared to other HERVs. Another possibility is
that these genes have an essential function for the cell’s normal life
cycle, and therefore they remained functional during evolution.
The recent dramatic progress in real-time PCR techniques enables
investigators to learn more about viral genes’ expression in human
breast cancer, but the interpretation of these results can be sometimes
deceiving. mRNA expression does not necessarily lead to active pro-
tein expression. Hence, it is essential to establish the biologic signif-
icance of an mRNA presence by showing that it was translated into
a protein and by further confirming that the protein is biologically
Figure 4. The effects of RNA interference on the endogenous expression of HERV-K-T47D-RT. (A) Western blot analysis of protein ex-
tracts purified from different clones of T47D cells stably transfected with the control pRetro-GFP-siRNA or with pRetro-RT-siRNA (two
different clones). The blots were incubated with the anti–T47D-RT antiserum. As a loading control, the same blots were incubated with
anti–β-actin antibody. (B) Densitometric quantitation of the Western blot data shown in panel (A), normalized with β-actin (white bars). RT
colorimetric activity assay was performed on the same protein extracts as in panel (A) (gray bars; a representative experiment out of
three). (C) Colorimetric RT activity assay was performed on the solubilized T47D cell–derived viral-like pellets (a representative experi-
ment out of three). Pellets were obtained by centrifuging (100,000g) T47D cell condition medium that was either untreated (white) or
treated with β-estradiol and progesterone (gray).
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Figure 5. HERV-K T47D-RT expression in human breast carcinoma tissues. (A) Paraffin-embedded sections from breast carcinoma biopsies
were subjected to indirect immunoflourescence staining using anti–T47D-RT antibody (a, b, e, and f) or NRS (normal rabbit serum) (c, d, g,
and h) and analyzed by CLSM. Representative image pairs of anti–T47D-RT and NRS are presented: RT-positive (a, c) or RT-negative (b, d)
tumor tissue; RT-positive (e, g) or RT-negative (f, h) normal adjacent tissue serial sections. (B) The distribution of the tumors’ HERV-K T47D-
RT staining level (AAI ratio; bars) and their cumulative percentages (lines). The cutoff point between positive and negative staining is
marked by arrow (AAI = 1.2). (C) Kaplan–Meier analysis of disease-free survival for two groups of patients: HERV-K T47D-RT–positive
(as measured by AAI ratios), at levels above the cutoff of 1.2 (red line); and HERV-K T47D-RT–negative, at levels below the cutoff (blue
line). (D) Kaplan–Meier analysis of overall survival for the same two groups of patients as in panel (C): HERV-K T47D-RT–positive (red line)
and HERV-K T47D-RT–negative (blue line). P values were calculated using log-rank and Wilcoxon tests.
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active and has an enzymatic activity. We have shown here that
the HERV-K-T47D-RT is expressed in different human breast can-
cer cell lines but not in the normal human breast cell line HB2.
These results support the assumption that the HERV-K-T47D-RT
is specific to human breast cancer. However, only in T47D cells the
HERV-K-T47D-RT protein was shown to be induced by the steroid
hormones estrogen and progesterone. Our results highly correlate
with a work that examined the mRNA expression of HERV-K-env
in different hormonally induced breast cancer cell lines [22]. Because
all tested breast cancer cell lines express the HERV-K-T47D-RT, al-
beit some express this protein constitutively, hormonal induction
probably depends on the presence of receptors to both steroid hor-
mones tested. The T47D cells express low levels of estrogen receptors
and high levels of progesterone receptors [24], whereas in MCF7,
this ratio is reversed such that estrogen receptors levels are high
[45] and the progesterone receptor levels are low [46]. Thus, it is
not surprising that the pattern of hormonal regulations in these
two cell lines is likely to be different. The common assumption is
that the hormonal regulation is gained by the hormone receptor
binding to specific response elements in the viral LTR promoter
[47]. In the MDA-MB-231 and BT549 cells that do not express ste-
roid receptors, there is a constitutively high expression of the HERV-
K-T47D-RT. This observation may result from the loss of hormonal
sensitivity that accompanies malignant conversion and causes unreg-
ulated constitutive expression of the HERV-K-RT.
Although it was previously shown by our group and others
[12,18,48] that the particles released from T47D cells exhibit an RT-
related activity, to the best of our knowledge, so far there is no report
connecting the relationship between the enzymatic activities and the
HERV-K-RT expression. The only HERV-K-RT expressed was a re-
combinant protein with low in vitro polymerase enzymatic activity
[20], similar to the HERV-K-T47D-RT studied herein. This low activ-
ity of the recombinant RTmay result from the requirements for addi-
tional mammalian cellular cofactors that are missing from the in vitro
reactions (such as retroviral NC protein, known to induce RT activity)
or from possible posttranslational modifications that take place only in
mammalian cells and not in bacteria. It is less likely that minor bacterial
contaminants inhibit the RT activity; as we have already expressed,
there were many retroviral RTs and all were very active after similar
purification procedures [28,49–51]. In addition, we show here that
over-expression of YFP-HERV-K-T47D-RT chimeric protein in human
cell lines leads to a dramatic increase in the cytoplasmic RT-associated
DNA polymerase activity. This activity was proved to be specific to the
YFP-HERV-K-T47D-RT enzyme, because mutation in the YIDD ac-
tive site abolished this activity. Furthermore, this conclusion is strongly
supported by the finding that the intracellular T47D endogenous RT-
related activity was significantly decreased because of a specific RNA in-
terference. These results clearly indicate that the HERV-K-T47D-RT
protein is expressed and is enzymatically active in the human breast can-
cer cell line T47D. Over-expression of YFP HERV-K-T47D-RT and
down-regulation of the endogenous HERV-K-T47D-RT did not have
any obvious effect neither on the transformed breast cancer cells mor-
phology nor on their growth rate. These results indicate that other viral
proteins might be involved in the tumorigenic process. We have also
shown that the retroviral-like particles released from hormonally induced
T47D cells contain the HERV-K-T47D-RT protein (data not shown).
Furthermore, a 20-fold induction of the RT-dependent DNA poly-
merase activity was observed in these particles released from T47D
cells treated with estrogen and progesterone. Because RT catalyzes a
vital step in the retroviral life cycle, the presence of such enzymati-
cally active RT in retroviral-like particles may suggest that these par-
ticles are infectious. Although no infectivity of HERV-K particles was
reported so far [47,52], recent studies deduce that there is a possibility
that HERV-K (HML-2) particles are infective in cultures cells [53–56].
Based on the examination of the insertion polymorphism levels, it
was suggested that the HERV-K (HML-2) family are active in present-
day humans [53]. Active elements are likely to have been inserted
quite recently in human evolution and are therefore present at low
allele frequencies. These active elements may lead to the develop-
ment of malignancies. Because the HERV-K-T47D-RT enzyme, iso-
lated in this study, belongs to the same HML-2 subfamily, the findings
described herein may give rise to questions about a possible infectivity
of the HERV-K-T47D-RT–containing particles. According to another
hypothesis, the enzymatically active HERV-K-RTmay play also a role
in retrotransposition. An active RT in cancer cells reinforces the hy-
pothesis that, like MMTV, HERV-K can retrotranspose endogenous
oncogenes or into tumor suppressor genes and thus promote tumori-
genesis [8]. There are evidences showing that retrotransposons of
HERV-K origin are responsible for polymorphism in the length of
the complement genes C3 [57] and C4 [58]. HERV-K sequences were
also located very close to the BRCA1 breast predisposition gene [59]
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DM indicates distal metastasis; ER, estrogen receptor; LR, local recurrence; PGR, progesterone
receptor.
*For consistency with our rating system, HERV-K-T47D-RT–positive expression was an AAI value
above the cutoff of 1.2.
†χ2 test.
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and close to the glucose-6-phosphate dehydrogenase (G6PD) gene
[60]. A third hypothesis suggests that the active RT enzyme generates
pseudogenes by reverse transcription and reintegration of cellular
mRNA. Some works suggested that the over-expression of different
RTs could lead to an increase in cDNAs and pseudogenes levels [61–63].
The presence of HERV-K-T47D-RTwas further tested in human
breast tumors. We have shown that the HERV-K-RT protein is ex-
pressed in 26% of breast carcinoma cases tested (28/110) and in 18%
of adjacent normal tissue tested (15/85). The HERV-K-RT expression
is highly associated with the overall survival’s poor prognosis. The re-
sults implicate that the HERV-K virus and its active RT enzyme may
be associated with human breast carcinogenesis. The expression of
HERV-K-RT in the normal tissue adjacent to the tumor may indi-
cate that HERV-K is expressed very early in the tumorigenic process.
These data correlate with the previously published results showing
that HERV-K ENV is expressed in 45% of the breast tumors and
in 18% of the adjacent normal tissue [21]. However, we must em-
phasize that this association is not necessarily an evidence of causation.
As tailoring personal patient treatment becomes more customary in
breast carcinoma treatment, there is a growing necessity in finding
additional biologic markers for determining suitable treatment. A
novel marker such as HERV-K-T47D-RT can have a great significance
because of its warning of poor prognosis that is independent of other
tumor markers.
Anti-RT drugs are vastly used in the treatment of retroviral dis-
eases (most notably AIDS, caused by HIV). In addition, RT inhibi-
tors have been proposed in differentiation therapy for cancer [64].
Several reviews report epidemiological data that support the con-
clusion that cancer incidence is reduced in HAART-treated HIV-
AIDS patients [65,66]. These data indicate that anti-RT drugs might
also help in preventing or treating breast cancers expressing an RT
marker. To conclude, the findings presented herein are consistent with
T47D-RT as a novel independent prognostic marker for breast can-
cer and provide evidence for the possible involvement of endogenous
retrovirus in human breast carcinoma.
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Figure W1. HERV-K-T47D-RT sequence alignment and phylogenetic analysis. (A) Alignment of the HERV-K-T47D-RT protein expected
sequence to known HERV-K-RT sequences: 1) The full ORF of the HERV-K-T47D-RT sequence that was isolated by us; 2) The HERV-K-RT
(clone 10.1) sequence isolated from bone marrow cell line [20]; 3) The pol sequence isolated from particles secreted from T47D cells
[18]; 4) The HERV-K-RT/HTDV sequence isolated from teratocarcinoma [27]; 5) The HERV-K-T47D-RT short sequence (1.4 kb) isolated by
us. A residue that is highly conserved represented by a dot in the consensus line, the others are in lower case and the symbols “!” and
“#” represent similar amino acids (Multalin Software). The siRNA primers area is marked in the black box, and the conserved YIDD motif
that was mutated is marked in the box with the broken line. (B) Phylogenetic analysis of the HERV-K-T47D-RT sequence. The HERV-K-
T47D-RT was compared with the pol region of known HERV-Ks and MMTV sequences: STPLU4 (HML-1), N8.4 (HML-2), P1.3 (HML-3),
M3.10 (HML-4), (HML-5), (HML-6), HERV-K-T47D1 [19], HERV-K10 [47], HERV-RT (clone 10.1) [20], HERV-K/HTDV [39], and MMTV. The
numbers represent the numbers as the alignment in panel (A).
Figure W2. Examination of the polyclonal antibody generated against the short recombinant HERV-K-T47D-RT. Western blot analysis of
blot containing lysates of E. coli BL21(pLysS) transformed with pT5-HERV-K/HTDV-RT uninduced (1) or induced with 1 mM IPTG (2) and
purified MMTV-RT antigen (66 kDa) (3). The blots were incubated with the anti–T47D-RT antibody (lanes 1–3). Identical blot with purified
MMTV-RT antigen was incubated with the anti–6His-MMTV-RT antibody as control (lane 4).
